Related Experiment Video
Updated: May 25, 2026
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
The genetics of uveal melanoma: an emerging framework for targeted therapy
1Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA. harbour@wustl.edu
Abstract:
Uveal melanoma is the second most common form of melanoma and the most common primary intraocular malignancy. Until recently, very little was known about the genetics of this aggressive cancer. Mutations in oncogenes and tumor suppressors that are common in other cancers are conspicuously absent in uveal melanoma. In recent years, however, uveal melanoma has begun to yield its secrets, and a fascinating picture is emerging of how it develops and progresses. Mutations in the G(q) alpha subunits, encoded by GNAQ and GNA11, appear to be early or perhaps initiating events that require further mutations for malignant transformation. On the other hand, mutations in the BRCA1-associated protein-1 (BAP1) appear to occur later and demarcate a molecular brink beyond which metastasis becomes highly likely. BAP1 mutations can also occur in the germline, leading to a distinctive cancer predisposition syndrome. These mutations appear to be key events that provide the potential for targeted therapy. This article will review the genetic findings in uveal melanoma over the past two decades and suggest important areas for future work.
Insights
Genetic mutations in GNAQ/GNA11 and BRCA1-associated protein-1 (BAP1) are key drivers of uveal melanoma development and metastasis. Understanding these genetic alterations offers potential for targeted cancer therapies.
Area of Science:
- Ophthalmology
- Oncology
- Cancer Genetics
Background:
- Uveal melanoma is the most common primary intraocular malignancy and the second most common melanoma subtype.
- Traditional cancer gene mutations are notably absent in uveal melanoma, necessitating unique genetic investigations.
- Recent advancements are revealing the specific genetic landscape driving uveal melanoma progression.
Purpose of the Study:
- To review key genetic findings in uveal melanoma over the past two decades.
- To elucidate the roles of specific gene mutations in uveal melanoma pathogenesis.
- To identify potential targets for future therapeutic strategies.
Main Methods:
- Review of genetic studies on uveal melanoma.
- Analysis of mutation patterns in oncogenes and tumor suppressors.
- Investigation of GNAQ, GNA11, and BAP1 gene alterations.
Main Results:
- Mutations in GNAQ and GNA11 appear to be early events in uveal melanoma development.
- Mutations in BRCA1-associated protein-1 (BAP1) are associated with later-stage disease and increased metastatic potential.
- Germline BAP1 mutations are linked to a specific cancer predisposition syndrome.
Conclusions:
- Specific genetic mutations, particularly in GNAQ/GNA11 and BAP1, are critical in uveal melanoma.
- These genetic insights provide a foundation for developing targeted therapies.
- Further research into uveal melanoma genetics is crucial for advancing treatment options.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase